Evalution the Effects of Raloxifene and Risedronate on Serum Biochemical Markers

Objective: Osteoporosis a progressive bone disease that is characterized by a decrease in bone mass which can lead to an increased risk of\udfracture. Osteoporosis is still a global public health problem. In recent years, many new osteoporosis drugs have become available but none of\udthem is totally curative. The aim of the present study was to evaluate and compare the effects of risedronate and raloxifene on bone mineral\uddensity (BMD) and bone turnover markers.\udMaterials and Methods: A total of ninety patients with postmenopausal osteoporosis were randomly divided into three groups receiving\udcalcium-vitamin D plus raloxifene, calcium-vitamin D plus risedronate, and only calcium-vitamin D (control group). Serum osteocalcin and\udcollagen type 1 cross-linked C-telopeptide (CTX) were measured before treatment and after 3, 6, 9 and 12 months of treatment. BMD was\udmeasured by Dual-Energy X-Ray absorptiometry (DEXA) before treatment and after 12 months of treatment.\udResults: Serum CTX levels were decreased significantly (p<0.001) in all groups from baseline to post therapy of 3 months and this decrease\udcontinued to the end of the study. Serum osteocalcin levels were decreased significantly (p<0.001) in treatment groups compared to control\udgroup. L1-L4 and femur total BMD was statistically lower in treatment groups compared to control group after 12 months of the therapy\ud(p<0.001 and p<0.05, respectively).\udConclusion: The results of the present study showed us that risedronate and raloxifene were both effective on bone mineral density and the\udeffect of both of them to do not differ not from each other in the treatment of osteoporosis. (Turkish Journal of Osteoporosis 2014;20: 110-6